secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001140361-25-000008
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore appoints Travis Coy as EVP, CFO, Head of Corporate Development effective Jan 1, 2025
--------------------------------------------------------------------------------

- Annual base salary $500,000; target cash bonus 40% of salary; sign-on bonus $200,000 in three installments.
- Grant of 274,033 options under 2021 Equity Incentive Plan, vesting over 4 years (25% at 1-year anniversary, then quarterly).
- Mr. Coy brings over 20 years at Eli Lilly, most recently VP, Head of Transactions and M&A.
- Severance: 18 months base salary plus 150% target bonus if terminated without cause within 18 months of change of control; 12 months base otherwise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125000008/0001140361-25-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125000008/ef20040795_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer